Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has announced a drug collaboration agreement with OpenAI, a prominent artificial intelligence (AI) research organization headquartered in San Francisco. As part of this collaboration, Lilly will utilize OpenAI’s advanced generative AI technologies to develop innovative antimicrobial treatments aimed at combating drug-resistant pathogens.
This partnership makes Lilly the second major pharmaceutical corporation to collaborate with OpenAI, following a similar agreement signed by Moderna (Nasdaq: MRNA) in April of this year.
Since its establishment in December 2015, OpenAI has reportedly developed multiple platforms to aid in drug development. These include the application of GPT-3 for generating new drug molecule candidates based on specific input parameters and a deep learning model known as CLIP, which can analyze medical images to identify potential health risks, thereby enhancing the efficiency of clinical trials.- Flcube.com
